Clinical Trials

Solid Tumors

NCT06031441 2026-03-06

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

250 enrolled

Phase 1 Active not recruiting

Locally Advanced Solid Tumors

NCT04250155 2026-02-24

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

195 enrolled

Solid Tumors

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Phase 1 Recruiting

50 enrolled

Advanced Solid Tumor

NCT06488716 2025-12-24

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Terminated

12 enrolled

Solid Tumour

NCT04276376 2025-12-01

ARIANES

Phase 2 Terminated

130 enrolled

Phase 2 Active not recruiting

Solid Tumor

NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

12 enrolled

Phase 1 Active not recruiting

Advanced Rare Malignant Solid Neoplasm

NCT03228537 2025-11-10

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

28 enrolled 17 charts

Mesothelioma, Malignant

NCT05434234 2025-11-10

A Study of YL201 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

312 enrolled

Phase 1 Active not recruiting

Advanced Solid Tumor

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

610 enrolled

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT07190833 2025-09-24

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Phase 1 Not yet recruiting

27 enrolled

Treatment-Refractory Solid Tumors

NCT05109442 2025-08-20

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase 1/2 Terminated

112 enrolled 28 charts

Advanced Solid Tumor

NCT05487235 2025-07-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

57 enrolled

Advanced Solid Tumors

NCT04975958 2025-06-22

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

47 enrolled

Locally Advanced Solid Tumor

NCT06719973 2025-06-17

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Phase 1 Withdrawn

Advanced Solid Tumors

NCT04896697 2025-05-29

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Phase 1/2 Recruiting

136 enrolled

Advanced Solid Tumor

NCT04642365 2025-05-21

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Phase 1 Terminated

49 enrolled 31 charts

Solid Tumors

NCT04996017 2025-03-13

AtezoMeso

Phase 3 Recruiting

162 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT05907980 2025-03-06

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Phase 1 Recruiting

219 enrolled

Solid Tumor

NCT06331598 2024-12-24

IMperator

Phase 2 Withdrawn

Solid Tumors

NCT06003621 2024-11-15

MoST-TAP

Phase 2 Recruiting

96 enrolled

Solid Tumor, Adult

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1/2 Withdrawn

Phase 2 Active not recruiting

Select Advanced Solid Tumors

NCT04185831 2024-08-22

MEGALiT

167 enrolled

Phase 2 Active not recruiting

Solid Tumor

NCT02478099 2024-05-03

MPDL3280A-treatment-IST-UMCG

81 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT03650348 2024-04-22

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

BreastGastrointestinalGenitourinaryOther solid neoplasm

41 enrolled

HER2-positive Breast Cancer

NCT04857138 2024-02-05

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

80 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Solid Tumors

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04471415 2023-06-12

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

61 enrolled

Advanced Solid Tumor

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

172 enrolled

Advanced Solid Tumor

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

186 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02715531 2021-07-09

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

243 enrolled

Solid Tumor

NCT03786419 2021-05-13

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Phase 2 Withdrawn

Mesothelioma, Malignant, Thoracic Neoplasms

NCT03264066 2021-05-11

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Phase 2 Completed

87 enrolled 24 charts

Solid Tumors

NCT02541604 2020-02-25

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Phase 1/2 Terminated

87 enrolled 41 charts

Solid Tumor

NCT02650713 2020-02-12

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

228 enrolled

Solid Tumors

NCT02304393 2019-12-13

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

140 enrolled

Solid Tumors

NCT02471846 2019-10-22

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

158 enrolled